Monopar TherapeuticsMNPR
13F holders, Q1 2024 (March 31)16holders
1famous investor
$0.68avg. 13F price*
At the end of Q1 2024, 16 institutions reported holding Monopar Therapeutics Inc. (MNPR) in their 13F filings. The largest holders were Millennium Management ($131K), Vanguard Group Inc. ($31K) and Geode Capital Management, LLC ($28K). One famous investor held it Israel Englander (0.0% of Millennium Management's portfolio).
- Company
- Monopar Therapeutics Inc.
- CUSIP
- 61023L108
- Latest filing quarter
- Q2 2024
History
Number of 13F holders
Total Exit/New Position Q1 2024
| Institutions | Total Value | |
|---|---|---|
| New Positions | 5 | $27K |
| Exits | 3 | $25K |
Ownership 16 holders
| Millennium Management | 0.00% | Add +555.7% | 192,381 | $131K |
| Vanguard Group Inc. | 0.00% | No change | 45,167 | $31K |
| Geode Capital Management, LLC | 0.00% | No change | 41,199 | $28K |
| HRT Financial LP | 0.00% | New | 32,113 | $21K |
| Gerber, LLC | 0.02% | No change | 28,005 | $19K |
| Virtu Financial LLC | 0.00% | Reduce -12.3% | 23,827 | $16K |
| Rappaport Reiches Capital Management, LLC | 0.00% | No change | 10,695 | $7K |
| Tower Research Capital LLC (TRC) | 0.00% | Add +117.1% | 7,856 | $5K |
| FMR LLC | 0.00% | New | 5,500 | $4K |
| NewEdge Advisors, LLC | 0.00% | New | 3,000 | $2K |
| UBS Group AG | 0.00% | Reduce -78.4% | 2,568 | $2K |
| Wells Fargo & Company | 0.00% | Add +4054.1% | 1,537 | $1K |
| Morgan Stanley | 0.00% | No change | 800 | $545 |
| Bank of America Corp. | 0.00% | New | 500 | $340 |
| Federation des caisses Desjardins du Quebec | 0.00% | No change | 80 | $54 |
| Royal Bank of Canada | 0.00% | New | 100 | $0 |
"% of holder's portfolio" is MNPR's weight in each manager's 13F, not the share of Monopar Therapeutics Inc. the manager owns.